Advanced

3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma.

Erixon, Martin LU ; Wieslander, Anders; Lindén, Torbjörn; Carlsson, Ola LU ; Jönsson, Jan Åke LU ; Simonsen, Ole LU and Kjellstrand, Per (2009) 12th Congress of the International-Society-for-Peritoneal-Dialysis In Peritoneal Dialysis International 29 Suppl 2. p.28-31
Abstract
OBJECTIVE: Glucose degradation products (GDPs) are important for the outcome of peritoneal dialysis (PD) treatment. The most cytotoxic GDP found in conventionally manufactured fluids, 3,4-dideoxyglucosone-3-ene (3,4-DGE), may in addition be recruited from 3-deoxyglucosone (3-DG). What happens with the GDPs in the fluid infused into patients during PD is not known. We investigated whether 3,4-DGE and 3-DG in PD fluid can be found in plasma during treatment. DESIGN: Patients on PD were dialyzed with a conventional PD fluid containing 43 micromol/L 3,4-DGE and 281 micromol/L 3-DG. Parallel experiments were performed in rats and in vitro with human plasma. The rats were dialyzed with a PD fluid containing 100 micromol/L 3,4-DGE and 200... (More)
OBJECTIVE: Glucose degradation products (GDPs) are important for the outcome of peritoneal dialysis (PD) treatment. The most cytotoxic GDP found in conventionally manufactured fluids, 3,4-dideoxyglucosone-3-ene (3,4-DGE), may in addition be recruited from 3-deoxyglucosone (3-DG). What happens with the GDPs in the fluid infused into patients during PD is not known. We investigated whether 3,4-DGE and 3-DG in PD fluid can be found in plasma during treatment. DESIGN: Patients on PD were dialyzed with a conventional PD fluid containing 43 micromol/L 3,4-DGE and 281 micromol/L 3-DG. Parallel experiments were performed in rats and in vitro with human plasma. The rats were dialyzed with a PD fluid containing 100 micromol/L 3,4-DGE and 200 micromol/L 3-DG. RESULTS: The 3,4-DGE concentration in the peritoneum declined at a much higher rate during the dwell than did the 3-DG concentration. However, 3,4-DGE was not detected in the plasma of patients or of rats during dialysis. The 3-DG concentration in plasma peaked shortly after infusion of fluid into the peritoneal cavity. The 3,4-DGE concentration during experimental incubation in plasma declined rapidly; the 3-DG concentration declined only 10% as rapidly (or less). CONCLUSION: During dialysis, 3,4-DGE could not be detected in plasma of either PD patients or rats, presumably because of its high reactivity. On the other hand, 3-DG may pass through the membrane and be detected in the blood. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Peritoneal dialysis fluid, glucose degradation products, 3, 3-DG, 4-DGE, plasma, advanced glycation end-products
in
Peritoneal Dialysis International
volume
29 Suppl 2
pages
28 - 31
publisher
Multimed Inc.
conference name
12th Congress of the International-Society-for-Peritoneal-Dialysis
external identifiers
  • WOS:000263937100004
  • PMID:19270226
  • Scopus:67449100957
ISSN
1718-4304
language
English
LU publication?
yes
id
e95d6855-0201-4419-b9ab-5450a77a7854 (old id 1370642)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19270226?dopt=Abstract
date added to LUP
2009-06-03 13:04:53
date last changed
2016-10-30 04:48:05
@misc{e95d6855-0201-4419-b9ab-5450a77a7854,
  abstract     = {OBJECTIVE: Glucose degradation products (GDPs) are important for the outcome of peritoneal dialysis (PD) treatment. The most cytotoxic GDP found in conventionally manufactured fluids, 3,4-dideoxyglucosone-3-ene (3,4-DGE), may in addition be recruited from 3-deoxyglucosone (3-DG). What happens with the GDPs in the fluid infused into patients during PD is not known. We investigated whether 3,4-DGE and 3-DG in PD fluid can be found in plasma during treatment. DESIGN: Patients on PD were dialyzed with a conventional PD fluid containing 43 micromol/L 3,4-DGE and 281 micromol/L 3-DG. Parallel experiments were performed in rats and in vitro with human plasma. The rats were dialyzed with a PD fluid containing 100 micromol/L 3,4-DGE and 200 micromol/L 3-DG. RESULTS: The 3,4-DGE concentration in the peritoneum declined at a much higher rate during the dwell than did the 3-DG concentration. However, 3,4-DGE was not detected in the plasma of patients or of rats during dialysis. The 3-DG concentration in plasma peaked shortly after infusion of fluid into the peritoneal cavity. The 3,4-DGE concentration during experimental incubation in plasma declined rapidly; the 3-DG concentration declined only 10% as rapidly (or less). CONCLUSION: During dialysis, 3,4-DGE could not be detected in plasma of either PD patients or rats, presumably because of its high reactivity. On the other hand, 3-DG may pass through the membrane and be detected in the blood.},
  author       = {Erixon, Martin and Wieslander, Anders and Lindén, Torbjörn and Carlsson, Ola and Jönsson, Jan Åke and Simonsen, Ole and Kjellstrand, Per},
  issn         = {1718-4304},
  keyword      = {Peritoneal dialysis fluid,glucose degradation products,3,3-DG,4-DGE,plasma,advanced glycation end-products},
  language     = {eng},
  pages        = {28--31},
  publisher    = {ARRAY(0x94c1950)},
  series       = {Peritoneal Dialysis International},
  title        = {3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma.},
  volume       = {29 Suppl 2},
  year         = {2009},
}